L1295
Lamivudine
≥98% (HPLC), nRTI inhibitor, powder
Synonym(s):
2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C8H11N3O3S
CAS Number:
Molecular Weight:
229.26
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Lamivudine, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
water: 10 mg/mL, clear
originator
GlaxoSmithKline
storage temp.
room temp
SMILES string
NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
InChI
1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
InChI key
JTEGQNOMFQHVDC-NKWVEPMBSA-N
Application
Lamivudine has been used to deplete the Hepatitis B Virus (HBV) covalently closed circular DNA (cccDNA) forms for the preparation of inverse nested PCR.
Biochem/physiol Actions
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Lamivudine
signalword
Warning
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
hcodes
Hazard Classifications
Aquatic Chronic 3 - Repr. 2 - STOT RE 2
target_organs
Blood
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Sharon L Walmsley et al.
The New England journal of medicine, 369(19), 1807-1818 (2013-11-08)
Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified
Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles
Tu T, et al.
Journal of virology, JVI-02007 (2018)
François Raffi et al.
The Lancet. Infectious diseases, 13(11), 927-935 (2013-10-01)
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. SPRING-2 is an ongoing phase